However, minimal activities were achieved against tumours harbouring actionable aberration(s) in FGFR1‐3, including FGFR1‐amplified SqCLC and gastric adenocarcinoma with FGFR2 polysomy or gene amplification.183, 184. Here, FGFR1 is linked to gastric adenocarcinoma.